These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 27830780)

  • 1. The road to restoring neural circuits for the treatment of Alzheimer's disease.
    Canter RG; Penney J; Tsai LH
    Nature; 2016 Nov; 539(7628):187-196. PubMed ID: 27830780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.
    Palop JJ; Mucke L
    Nat Neurosci; 2010 Jul; 13(7):812-8. PubMed ID: 20581818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.
    Zeng Y; Zhang J; Zhu Y; Zhang J; Shen H; Lu J; Pan X; Lin N; Dai X; Zhou M; Chen X
    J Neurochem; 2015 Apr; 133(1):38-52. PubMed ID: 25661995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New connections: Amyloid-β, calcium, and the synapse.
    Ferrarelli LK
    Sci Signal; 2017 Jul; 10(487):. PubMed ID: 28698217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [β Amyloid Hypothesis in Alzheimer's Disease:Pathogenesis,Prevention,and Management].
    Zhang H; Zheng Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):702-708. PubMed ID: 31699204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS
    Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Pathological Benefit of Twendee X in Alzheimer's Disease Transgenic Mice with Chronic Cerebral Hypoperfusion.
    Liu X; Yamashita T; Shang J; Shi X; Morihara R; Huang Y; Sato K; Takemoto M; Hishikawa N; Ohta Y; Abe K
    J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1993-2002. PubMed ID: 31029568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic Dysfunction in Alzheimer's Disease: Aβ, Tau, and Epigenetic Alterations.
    Li K; Wei Q; Liu FF; Hu F; Xie AJ; Zhu LQ; Liu D
    Mol Neurobiol; 2018 Apr; 55(4):3021-3032. PubMed ID: 28456942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease.
    Grace EA; Rabiner CA; Busciglio J
    Neuroscience; 2002; 114(1):265-73. PubMed ID: 12207971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.
    Steinitz M
    Expert Opin Biol Ther; 2008 May; 8(5):633-42. PubMed ID: 18407766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid.
    Nimmrich V; Ebert U
    Rev Neurosci; 2009; 20(1):1-12. PubMed ID: 19526730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular prion protein as a therapeutic target in Alzheimer's disease.
    Laurén J
    J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is amyloid-β harmful to the brain? Insights from human imaging studies.
    Jagust W
    Brain; 2016 Jan; 139(Pt 1):23-30. PubMed ID: 26614753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model.
    Cheng XR; Zhou WX; Zhang YX
    Ageing Res Rev; 2014 Jan; 13():13-37. PubMed ID: 24269312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.